Literature DB >> 9301985

In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.

M A Cohen1, M D Huband, J W Gage, S L Yoder, G E Roland, S J Gracheck.   

Abstract

Clinafloxacin and trovafloxacin are two new fluoroquinolones for which few comparative data are available. When MICs of ciprofloxacin against Gram-positive and Gram-negative nosocomial species were compared, clinafloxacin was the most potent although trovafloxacin was also more active than ciprofloxacin against Staphylococcus aureus and enterococci. All three drugs were bactericidal. Clinafloxacin displayed the lowest frequency of resistance, approximating 10(-11). Development of resistance studies over 13-14 passages in the presence of drug revealed a 32-fold increase in MIC of clinafloxacin against S. aureus compared with 512- and 1024-fold for trovafloxacin and ciprofloxacin respectively, although the three drugs were comparable against Enterococcus faecalis and the Gram-negative bacilli.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301985     DOI: 10.1093/jac/40.2.205

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.

Authors:  C L Clark; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

Review 2.  Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors:  C E Nord
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

Review 3.  The prevention of antibiotic resistance during treatment.

Authors:  J D Williams; A M Sefton
Journal:  Infection       Date:  1999       Impact factor: 3.553

4.  Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.

Authors:  G Siami; N Christou; I Eiseman; K J Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

5.  Comparative activities of clinafloxacin against gram-positive and -negative bacteria.

Authors:  L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.

Authors:  H Oh; N El Amin; T Davies; P C Appelbaum; C Edlund
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

Review 8.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Drug interactions with clinafloxacin.

Authors:  E J Randinitis; C W Alvey; J R Koup; G Rausch; R Abel; N J Bron; N J Hounslow; A B Vassos; A J Sedman
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

10.  Comparison of agar dilution, disk diffusion, MicroScan, and Vitek antimicrobial susceptibility testing methods to broth microdilution for detection of fluoroquinolone-resistant isolates of the family Enterobacteriaceae.

Authors:  C D Steward; S A Stocker; J M Swenson; C M O'Hara; J R Edwards; R P Gaynes; J E McGowan; F C Tenover
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.